Irritable Bowel Syndrome is a common disorder of gut-brain interaction characterised by recurrent abdominal pain associated with defaecation and changes in stool frequency or stool form. It is a functional gastrointestinal disorder, although the term functional does not imply that the bowel is structurally normal in every biological respect or that symptoms are psychological. IBS is diagnosed clinically using established symptom-based criteria after appropriate consideration of alternative diagnoses.
Major patterns include IBS with predominant constipation, IBS with predominant diarrhoea and mixed patterns in which constipation and diarrhoea alternate. Symptoms can include bloating, urgency, incomplete evacuation and mucus in stools. IBS differs fundamentally from inflammatory bowel diseases because it does not characteristically produce destructive intestinal inflammation, ulceration or increased colorectal cancer risk. It can nevertheless produce substantial and persistent impairment of quality of life.
The mechanisms of Irritable Bowel Syndrome are multifactorial. Altered communication between the gastrointestinal tract and nervous system can change how intestinal sensations are perceived and how motility is regulated. Visceral hypersensitivity means that normal or modest intestinal distension may be experienced as disproportionately uncomfortable. Changes in intestinal motility can contribute to diarrhoea, constipation or variable bowel habits. Some people develop IBS after an episode of infectious gastroenteritis, a pattern known as post-infectious IBS.
Alterations in the gut microbiome have been investigated extensively, although no single microbial abnormality explains the condition and microbiome testing is not a routine diagnostic requirement. Food composition, fermentation, intestinal transit, bile-acid handling and immune signalling may also contribute in particular individuals. These interacting mechanisms explain why no single treatment works for every patient and why management is often tailored to the dominant symptoms and triggers.
Diagnosis of Irritable Bowel Syndrome is generally based on recurrent abdominal pain associated with bowel habit changes over an appropriate period, together with assessment for features suggesting another disease. The pain may improve or worsen with defaecation, and its relationship to bowel movements is diagnostically relevant. Basic blood tests may be used to identify anaemia, inflammation or other abnormalities depending on the presentation.
Testing for coeliac disease can be appropriate in people with diarrhoea-predominant symptoms, while stool tests may be used when inflammatory or infectious conditions are plausible. Colonoscopy is not automatically required for every person with IBS, particularly when symptoms fit established criteria and there are no concerning features, although age, family history and symptom characteristics influence decisions. Rectal bleeding, unexplained weight loss, persistent anaemia, nocturnal symptoms or other atypical findings may require investigation for alternative disease.
Dietary factors can strongly influence Irritable Bowel Syndrome, but there is no universal IBS diet. Some people identify symptoms after particular carbohydrates, large meals, high-fat foods, caffeine or alcohol. A low-FODMAP dietary approach can reduce symptoms in some patients by limiting poorly absorbed, fermentable carbohydrates that increase luminal water and gas, but it is not intended to be an unnecessarily permanent restrictive diet. Ideally, dietary restriction is structured and followed by gradual reintroduction to identify individual tolerance.
Adequate fibre can be useful for constipation-predominant IBS, although the type of fibre matters because rapidly fermentable fibre may worsen bloating in some individuals. Fluid intake, meal regularity and physical activity can also influence bowel function. Nutritional adequacy is important because extensive self-imposed food restriction can create deficiencies and worsen quality of life. Dietary management should therefore target reproducible symptoms rather than encourage increasingly restrictive eating.
Treatment of Irritable Bowel Syndrome is symptom-directed and may involve dietary, behavioural and pharmacological approaches. Constipation-predominant IBS may respond to soluble fibre, osmotic laxatives or medicines specifically affecting intestinal secretion or motility in selected patients. Diarrhoea-predominant IBS can sometimes be managed with antimotility treatment, while abdominal pain may respond to antispasmodic medicines or selected neuromodulating drugs. Neuromodulators can influence visceral pain processing even when depression is not the primary treatment target.
Psychological interventions such as cognitive behavioural therapy or gut-directed hypnotherapy can help some patients because the gut-brain interaction is a biological component of the disorder. Regular physical activity and adequate sleep may also support symptom control. Treatment is often iterative because symptom patterns change and an intervention that improves one symptom can aggravate another, such as excessive fibre increasing bloating.
Irritable Bowel Syndrome is distinct from inflammatory diseases despite some superficial symptom overlap. IBS does not normally cause intestinal ulceration, strictures, fistulas or significant systemic inflammation. Inflammatory Bowel Disease, particularly Crohn's Disease and Ulcerative Colitis, can cause diarrhoea, abdominal pain and urgency but is associated with objective inflammatory pathology. Coeliac Disease can also produce bloating, diarrhoea and nutritional deficiencies and therefore may need consideration in relevant presentations.
Diverticular Disease can cause abdominal symptoms that overlap with IBS, particularly in older adults. The distinction matters because treatment and long-term monitoring differ substantially. Biomarkers such as faecal calprotectin can sometimes help distinguish inflammatory intestinal disease from functional disorders in appropriate patients, although no test independently diagnoses IBS. A normal investigation can be reassuring when interpreted alongside a typical symptom pattern, but new or changing symptoms still require appropriate reassessment.
IBS can fluctuate over many years and may coexist with other gastrointestinal conditions. Symptom severity is not necessarily proportional to any measurable abnormality in bowel function, and stress can influence symptoms without being their sole cause. The relationship between psychological state and IBS should not be reduced to the idea that symptoms are imaginary or simply caused by anxiety.
Brain-gut signalling, autonomic activity, visceral sensitivity and immune mechanisms provide biological pathways through which stress and emotional states can alter gastrointestinal function. Conversely, persistent gastrointestinal symptoms can themselves increase anxiety and reduce daily functioning. Some people have long symptom-free periods, while others experience chronic symptoms requiring sustained management. The disorder does not generally progress to bowel damage or colorectal cancer, but unnecessary investigations, restrictive diets and repeated medication changes can create their own burdens.
The term Irritable Bowel Syndrome reflects the central concept of an irritable or hypersensitive bowel but does not imply that the bowel is literally inflamed. A common misconception is that IBS and IBD are two names for the same illness; they are not. IBS is primarily a disorder of gastrointestinal function and gut-brain interaction, whereas IBD involves immune-mediated or otherwise sustained intestinal inflammation with objective tissue changes. Another misconception is that every person with IBS requires a special diet indefinitely.
Individual tolerance varies, and restrictive approaches should be used thoughtfully. IBS also should not be diagnosed solely because routine tests are normal; a positive symptom-based clinical diagnosis is preferable when criteria are fulfilled and serious alternative conditions have been reasonably considered. Its significance lies in the large burden of symptoms it can impose despite the absence of the destructive intestinal pathology characteristic of inflammatory disease.
